Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;167(4):453-65.
doi: 10.1111/bjh.13064. Epub 2014 Aug 12.

The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

Mike A Laffan  1 , Will Lester, James S O'Donnell, Andrew Will, Robert Campbell Tait, Anne Goodeve, Carolyn M Millar, David M Keeling
Affiliations
Review

The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

Mike A Laffan et al. Br J Haematol. 2014 Nov.
No abstract available

Keywords: United Kingdom Haemophilia Centre Doctors Organization; diagnosis; guideline; management; von Willebrand.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-Interest Disclosure: ML has received speaker fees from Bayer, Octapharma and Pfizer, advisory board fees from CSL-Behring, Pfizer, Bayer and Grifols and research support from Bayer and CSL Behring. WL has received speaker fees and travel support from CSL and advisory board fees from Octapharma. JSOD has served on the speakers bureau for Baxter, Bayer, Novo Nordisk, Leo Pharma and Octapharma; served on the advisory boards of Baxter, Bayer, Octapharma and Pfizer and received research grant funding awards from Baxter, Bayer and Novo Nordisk. AW has no declarations of interest relating to this guideline. AG has received speaker fees from Octapharma and VWF mutation database support from CSL Behring. CMM has received research grant funding award and speaker fees from CSL Behring and Baxter and served on advisory boards for CSL and NovoNordisk. DMK has served on advisory boards for Baxter, CSL, Bayer, Pfizer and NovoNordisk. RCT has received speaker and/or consultancy fees from Baxter, Pfizer & Bayer

Figures

Figure 1
Figure 1
Predictive value of bleeding symptoms in diagnosis of type 1 VWD. Reproduced with permission, from Tosetto, A., Rodeghiero, F., Castaman, G., Goodeve, A., Federici, A.B., Batlle, J., Meyer, D., Fressinaud, E., Mazurier, C., Goudemand, J., Eikenboom, J., Schneppenheim, R., Budde, U., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F. & Peake, I. (2006) A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). Journal of Thrombosis & Haemostasis, 4, 766-773. Copyright © 2006, John Wiley and Sons
Figure 2
Figure 2
An algorithm for the investigation of suspected von Willebrand disease. VWF, von Willebrand factor; VWF:Ag, VWF antigen; VWF:RCo, ristocetin cofactor activity; VWFCB, collagen binding activity; FVIII, factor VIII; FVIII:C, Factor VIII coagulant activity; GPIb, glycoprotein Ib; HMW, high molecular weight; RIPA, ristocetin-induced platelet agglutination.
See this image and copyright information in PMC

References

    1. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus “variants”. Blood. 1980;56:712–716. - PubMed
    1. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165–172. - PubMed
    1. Batlle J, Lopez-Fernandez MF, Fraga EL, Trillo AR, Perez-Rodriguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagulation & Fibrinolysis. 2009;20:89–100. - PubMed
    1. Berntorp E, Abshire T von Willebrand Disease Prophylaxis Network Steering, C. The von Willebrand disease prophylaxis network: exploring a treatment concept. Journal of Thrombosis & Haemostasis. 2006;4:2511–2512. - PubMed
    1. Berntorp E, de Moerloose P, Ljung RCR. The role of prophylaxis in bleeding disorders. Haemophilia. 2010;16 Suppl 5:189–193. - PubMed

Publication types